Contemporary Update of Retinoblastoma in China: Three-Decade Changes in Epidemiology, Clinical Features, Treatments, and Outcomes

Luo, Yunfeng; Zhou, Chuandi; He, Fanglin; Fan, Jiayan; Wen, Xuyang; Ding, Yi; Han, Yang; Ding, Jingwen; Jin, Mei; Liu, Zhenyin; Sha, Wei E. I.; Han, Mei; Yuan, Hongfeng; Sun, Hong; Xiao, Yi-shuang; Wu, Li; Wang, Jian-Cang; Li, Yangjun; Yang, Huasheng; Yu, Jiang; Gong, Jun; Xu, Yuxin; Yang, Wen; Gao, Zhuo; Mei, Lixin; Ye, Juan; Liu, Hu; Chen, Zhijun; Xue, Shangcai; Liu, Rong; Chen, Hong; Lu, Wei; Liao, Hongfei; Guo, Qing; Cui, Jizhe; Zhu, Dan; Lü, Fang; Tang, Song; Wu, Yu; Yangkyi, Tseden; Zhang, Guanghong; Wubuli, Miershalijiang; Guo, Haipeng; Wang, Xian; He, Yanjin; Sheng, Xunlun; Wang, Qing; Tan, Jia; Liang, Jianhong; Sun, Xiantao; Zhang, Jing; Ji, Xunda; Jin, Liwen; Zhao, Junyang; Yang, Xinji; Jia, Renbing

doi:10.1016/j.ajo.2021.09.026

Cited by 12 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7,30,31 We adhered to a low threshold when performing enucleation, so this may be the reason we had a relatively low death rate, which was approximately the same as that in Argentinian, 34 Mexican, 35 and Asian Indian cohorts 36 but far higher than that in other studies. 6,7,29 Most enucleated eyes in our study had low-stage pathologic classification, and the presence of HRFs dictated post enucleation chemotherapy. The number of eyes of patients who had undergone neoadjuvant chemotherapy that had HRFs was lower than that of patients with primarily enucleated eyes, at 50% and 63%, respectively, similar to the findings Zhao et al (p = 0.01).…”

Section: Discussionmentioning

confidence: 80%

Retinoblastoma treatment in a Brazilian population. Presentation and long‐term results

Bonanomi,

de Almeida,

Hollaender

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

IntroductionRetinoblastoma is a malignant tumor with a high cure potential when proper therapy is used. The purpose of this paper is to report the clinical features and outcomes of patients with retinoblastoma who were treated with a combination of local and systemic chemotherapy‐based protocols.MethodWe retrospectively studied patients treated with systemic chemotherapy plus local treatment between 2003 and 2015 with a follow‐up ≥2 years. We correlated clinical and pathological characteristics with decimal visual acuity (VA) and death.ResultsAmong 119 patients, 60% had unilateral disease (UNI), and 52% were male. The median presentation age was 19.5 months, 10% had a positive family history, and the most frequent sign was leukocoria (68.8%). Advanced disease was more frequent in eyes with UNI (98.4%) than in eyes with bilateral retinoblastoma (BIL: 55.3%). Enucleation was performed in 97% of UNI eyes and in 55.8% of BIL eyes. The overall globe salvage was 26.6%, 44.25% of BIL eyes. Bilateral enucleation was required in 5%. High‐risk pathologic features occurred in 50% and 37% of eyes enucleated without and with neoadjuvant chemotherapy, respectively. High‐risk features were related to the presence of goniosynechiae in the pathologic specimen and were more frequent in children younger than 10 months or older than 40 months. Extraocular disease was present in 5% of patients, and the death rate related to metastasis of the tumor was 8%. The final VA was ≥ 0.7 in 72.8% and ≥0.1 in 91% of BIL patients.ConclusionsTreatment of retinoblastoma with conservative systemic‐based chemotherapy was associated with an excellent survival rate (92%). Albeit the low overall globe salvage rate, in BIL patients, approximately half the eyes were conserved, and a satisfactory functional visual result was achieved The evaluated protocol is an important treatment option, especially in developing countries.

show abstract

Section: Discussionmentioning

confidence: 80%

Retinoblastoma treatment in a Brazilian population. Presentation and long‐term results

Bonanomi,

de Almeida,

Hollaender

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…In addition, Rb can cause intracranial and distant metastasis, which can easily cause the death of Rb patients, posing a great threat to the quality of life of patients and their offspring (34,35). According to statistics, about 9,000 newborns are diagnosed with Rb each year, and about 3,000 children die of Rb (36,37). Therefore, finding biomarkers for early diagnosis of Rb is of great significance to improve the diagnosis and treatment of Rb and the prognosis of children (38).…”

Section: Discussionmentioning

confidence: 99%

The clinical diagnostic value of plasma miR-592 and miR-217-3p levels in retinoblastoma

Huang

Luo

et al. 2022

J Med Biochemistry

View full text Add to dashboard Cite

目的：研究血浆miR-592和miR-217-3p在视网膜母细胞瘤（Rb）中的异常表达，探讨其表达水平对Rb的临床诊断价值。方法：选取2018年1月至2019年1月到南昌市洪都中医院就诊的100例Rb患者为Rb组，同期来体检中心就诊的100例健康患者为对照组. 采用实时荧光定量PCR（qRT-PCR）检测所有受试者血浆miR-592和miR-217-3p的表达水平；分析血浆miR-592和miR-217-3p水平与Rb临床病理特征的关系；Pearson 相关分析评估了血浆 miR-592 和 miR-217-3p 水平与总生存率之间的关系。结果： Rb组血浆miR-592和miR-217-3p水平显着高于对照组（p < 0.0001），且miR-592的表达与家族遗传史显着相关（p＜ 0.0001)、肿瘤偏倚( p =0.0081)、淋巴结转移( p =0.0048)和病理分级( p =0.0025)，miR-217-3p的表达与家族遗传史显着相关( p＜0.0001)，视神经浸润（p＜0.0001）、淋巴结转移（p = 0.0090）、病理分级（p＜0.0001)。miR-592和miR-217-3p的高表达是Rb更严重的病理表现，随着miR-592（r=-0.2276，p =0.0052）和miR的升高，患者的总生存期显着缩短-217-3p 水平（r=-0.6461，p＜0.0001）。结论： miR-592和miR-217-3p在Rb患者血浆中高表达，其升高的水平呈现Rb严重的病理表现和缩短的总生存期，有望成为Rb临床诊断的生物标志物。

show abstract

“…If the tumor spreads to the entire eyeball or body, the survival rate is greatly reduced ( 3 , 4 ). The 1-, 3-, and 5-year overall survival rates of patients with retinoblastoma are 95%, 86%, and 83%, respectively ( 5 ).…”

Section: Introductionmentioning

confidence: 99%

Anemia and Bone Marrow Suppression After Intra-Arterial Chemotherapy in Children With Retinoblastoma: A Retrospective Analysis

et al. 2022

Self Cite

View full text Add to dashboard Cite

BackgroundRetinoblastoma (Rb) is a common ocular malignant tumor in children. Intra-arterial chemotherapy (IAC) has been widely used in children with Rb and has achieved an ideal therapeutic effect. However, IAC has side effects, including anemia and bone marrow suppression, for which explicit evidence on the risk factors is lacking. This study aimed to evaluate the covariates that may affect the occurrence of anemia and bone marrow suppression in children with Rb after IAC.MethodsChildren with Rb admitted between May 2019 and January 2021 were included into the study. The differences in the number of children with anemia and bone marrow suppression before and after IAC according to different covariates were recorded. All potential impact factors were included into the univariate and multivariate regression models to identify the related covariates of post-IAC anemia and bone marrow suppression.ResultsData of 282 children with Rb were retrospectively collected. After IAC, children with Rb had increased severities of anemia (p <0.0001, chi-square test) and bone marrow suppression (p = 0.001, chi-square test). Moreover, the number of children with Rb who had an increased cross-level change in the severity of anemia and degree of bone marrow suppression was 80 (41.24%) and 64 (32.49%), respectively. The univariate regression analysis showed that numerous factors (such as pre-IAC intravenous chemotherapy, results of pre-IAC routine blood tests, and some serological indicators for liver and kidney function) affected the anemia severity and degree of bone marrow suppression in children with Rb after IAC. Additionally, the predictive model of the multivariate regression could predict anemia and bone marrow suppression.ConclusionChildren with Rb may have an increased risk of anemia and bone marrow suppression after IAC, but this is temporary and can be influenced by several factors. Therefore, IAC should be maintained as the standard of care. We generated predictive equations for predicting anemia severity and degree of bone marrow suppression, which can guide the prediction and timely control of anemia and bone marrow suppression after IAC.

show abstract

Contemporary Update of Retinoblastoma in China: Three-Decade Changes in Epidemiology, Clinical Features, Treatments, and Outcomes

Cited by 12 publications

References 29 publications

Retinoblastoma treatment in a Brazilian population. Presentation and long‐term results

Retinoblastoma treatment in a Brazilian population. Presentation and long‐term results

The clinical diagnostic value of plasma miR-592 and miR-217-3p levels in retinoblastoma

Anemia and Bone Marrow Suppression After Intra-Arterial Chemotherapy in Children With Retinoblastoma: A Retrospective Analysis

Contact Info

Product

Resources

About